CA2873536A1 - Polypeptide loaded poca nanoparticles for oral administration - Google Patents

Polypeptide loaded poca nanoparticles for oral administration Download PDF

Info

Publication number
CA2873536A1
CA2873536A1 CA2873536A CA2873536A CA2873536A1 CA 2873536 A1 CA2873536 A1 CA 2873536A1 CA 2873536 A CA2873536 A CA 2873536A CA 2873536 A CA2873536 A CA 2873536A CA 2873536 A1 CA2873536 A1 CA 2873536A1
Authority
CA
Canada
Prior art keywords
nanoparticles
peptide
nanoparticle
exendin
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2873536A
Other languages
English (en)
French (fr)
Inventor
Sean Matthew Cleveland
Mark Andrew Paulik
Stefan Salomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CA2873536A1 publication Critical patent/CA2873536A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2873536A 2012-05-16 2013-05-16 Polypeptide loaded poca nanoparticles for oral administration Abandoned CA2873536A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647633P 2012-05-16 2012-05-16
US61/647,633 2012-05-16
PCT/IB2013/000964 WO2013171570A1 (en) 2012-05-16 2013-05-16 Polypeptide loaded poca nanoparticles for oral administration

Publications (1)

Publication Number Publication Date
CA2873536A1 true CA2873536A1 (en) 2013-11-21

Family

ID=48577784

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873536A Abandoned CA2873536A1 (en) 2012-05-16 2013-05-16 Polypeptide loaded poca nanoparticles for oral administration

Country Status (10)

Country Link
US (1) US20150342897A1 (enExample)
EP (1) EP2849775A1 (enExample)
JP (1) JP2015523332A (enExample)
KR (1) KR20150010953A (enExample)
CN (1) CN104411321A (enExample)
AU (1) AU2013261214A1 (enExample)
CA (1) CA2873536A1 (enExample)
IN (1) IN2014DN09297A (enExample)
RU (1) RU2014150850A (enExample)
WO (1) WO2013171570A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104799440B (zh) * 2014-01-23 2016-06-08 香港纺织及成衣研发中心有限公司 改善代谢综合症的功能服及其制造方法
CN105342999A (zh) * 2014-08-18 2016-02-24 山东绿叶制药有限公司 艾塞那肽口服纳米粒
CN109675020B (zh) * 2019-01-11 2021-05-04 浙江大学 一种口服glp-1多肽类纳米制剂及其制备方法和应用
WO2022132454A1 (en) 2020-12-18 2022-06-23 Spectrum Brands, Inc. Grooming tool for animal and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
DK1019077T4 (da) 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc Hidtil ukendte exendinagonistforbindelser
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ,インコーポレイテッド 新規なエキセンジンアゴニスト化合物
JP2001523688A (ja) 1997-11-14 2001-11-27 アミリン・ファーマシューティカルズ,インコーポレイテッド 新規エキセンジン・アゴニスト化合物
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 glp-1 유도체
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
MX2007016039A (es) 2005-06-17 2008-10-27 Univ North Carolina Metodos, sistemas y materiales de fabricacion de nanoparticulas.
US20080138418A1 (en) * 2006-12-07 2008-06-12 Tong Shen Enterprise Co., Ltd. Nanoparticles composed of alkyl-cyanoacrylate polymers
CN101896337B (zh) 2007-10-12 2013-10-30 流体科技公司 用于生产颗粒和图案化膜的系统和方法

Also Published As

Publication number Publication date
CN104411321A (zh) 2015-03-11
RU2014150850A (ru) 2016-07-10
KR20150010953A (ko) 2015-01-29
IN2014DN09297A (enExample) 2015-07-10
AU2013261214A1 (en) 2014-11-20
EP2849775A1 (en) 2015-03-25
WO2013171570A1 (en) 2013-11-21
US20150342897A1 (en) 2015-12-03
JP2015523332A (ja) 2015-08-13

Similar Documents

Publication Publication Date Title
Makhlof et al. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery
Song et al. Synthesis of CSK-DEX-PLGA nanoparticles for the oral delivery of exenatide to improve its mucus penetration and intestinal absorption
Chalasani et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin
Araujo et al. In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy
Sonia et al. An overview of natural polymers for oral insulin delivery
Chen et al. Long-acting release formulation of exendin-4 based on biomimetic mineralization for type 2 diabetes therapy
Hinds et al. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis
Shrestha et al. Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model
Ahn et al. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan
CN102908627B (zh) 用于口服胰岛素递送的pH敏感性纳米粒子
Seo et al. Sustained release of exendin 4 using injectable and ionic-nano-complex forming polymer hydrogel system for long-term treatment of type 2 diabetes mellitus
Ren et al. Utilization of PLGA nanoparticles in yeast cell wall particle system for oral targeted delivery of exenatide to improve its hypoglycemic efficacy
EP3099293B1 (en) Nanoencapsulation of hydrophilic active compounds
Zaiki et al. Critical material designs for mucus-and mucosa-penetrating oral insulin nanoparticle development
Kumeria et al. Enteric polymer-coated porous silicon nanoparticles for site-specific oral delivery of IgA antibody
Alfatama et al. A comprehensive review of oral chitosan drug delivery systems: Applications for oral insulin delivery
US20150342897A1 (en) Polypeptide loaded poca nanoparticles for oral administration
US20100143484A1 (en) Oral submicron particle delivery system for proteins and process for its production
CN115190795A (zh) 聚乙二醇化尿酸酶的制剂和剂量
Chauhan et al. Therapeutic advancements in the management of diabetes mellitus with special reference to nanotechnology
CN102657871B (zh) 一种口服缓释制剂、包载材料及制备方法
Sharmah et al. Insight into the drug delivery efficacy and anti-diabetic potential of cyclodextrin against hyperglycemia
Bouttefeux et al. Delivery of peptides via the oral route: diabetes treatment by peptide-loaded nanoparticles
Zhang et al. Strategies to Enhance the Therapeutic Efficacy of GLP‐1 Receptor Agonists through Structural Modification and Carrier Delivery
Son et al. Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20170516